CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: Mogamulizumab, a de-fucosylated anti-CCR4 antibody, reduces the levels of CCR4+ T cells and CCR4+ Tregs in patients with cutaneous T-cell lymphoma (CTCL), which may in turn improve their immune profiles [152].